Content area
Abstract
Aims Comparing the effect of intravitreal versus posterior subtenon injection of triamcinolone acetonide in treatment of diabetic macular edema. Settings and Design The study was conducted at Ophthalmology Department, Benha University Hospital in the period from march 2016 till september 2016. Material and methods This is prospective randomized longitudinal interventional comparative study including 30 eyes of patients with DME. Patients were divided into two groups. Group I included 15 eyes that received 4 mg of intravitreal triamcinolone acetonide injection. Group II comprised 15 eyes that received 40 mg of subtenon triamcinolone acetonide injection. Patients will be examined in the first post-injection day, then at 1st, 4th, 12th week interval after injection. At each visit full ophthalmological examination will be done. Central Macular Thickness (CMT) measurement with optical coherence tomography (at the 4th and 12th week). Statistical analysis Statistical Package of Social Sciences version 20 was used. P value of less than or equal (0.05) was considered statistically significant. Results There was no significant difference at 1 and 3 months (P > 0.05) as regards their post-treatment outcome for visual acuity and macular thickness. There was statistically significant difference in IOP change after 1 and 3 months after injection between the two groups, the change of IOP in the intravitreal injection group was greater than that of the posterior subtenon injection group. Conclusions Subtenon triamcinolone acetonide achieves results comparable to intravitreal injection as regards the reduction in CMT and the improvement in VA. However, Subtenon triamcinolone acetonide is safer.